Wells Fargo Initiates Coverage On Scribe Therapeutics with Overweight Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Neutral 55.7%

Neg 0% Neu 55.7% Pos 0%

Wells Fargo analyst Yanan Zhu initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Overweight rating and announces Price Target of $60.